A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

Premenopausal Breast Cancer Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01546649
• Other study ID #: TAP-144-SR(6M)IP/CPH-202
• Secondary ID: JapicCTI-121762U
• Status: Completed
• Phase: Phase 3
• First received: February 28, 2012
• Last updated: October 22, 2015
• Start date: April 2012
• Est. completion date: December 2014

Study information

• Verified date: October 2015
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 167
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. The participant has histopathologically-confirmed primary breast cancer in Japanese.

2. The participant is aged 20 years or older when informed consent is obtained

3. The participant has estrogen receptor (ER)-positive tumor cells and/or progesterone receptor (PgR)-positive primary tumor. And HER-2 is negative.

4. The participant has breast cancer in the clinical stages of T1-T3, N-any and M0 by TNM classification (the seventh edition, proposed by UICC in 2009). (No distant metastasis to lung, liver and bone should be confirmed on the image-based diagnosis at study enrollment. The image taken within 12 weeks prior to study enrollment is also available for the diagnosis.) The number of axillary lymph node metastasis is not limited.

5. Any operative procedure for breast cancer is acceptable. In principle, after breast-conserving surgery, the participant will receive postoperative radiation to the conserving breast.

6. Neoadjuvant chemotherapy and adjuvant chemotherapy prior to study enrollment are acceptable. (It is advisable the same kind of chemotherapy is performed at each site.)

7. The participant has a history of regular menstrual periods within 12 weeks prior to study enrollment, or the participant has FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more measured within 12 weeks prior to study enrollment. The participant has not had a chemical menopause (i.e., FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more) within 12 weeks after completing adjuvant chemotherapy.

8. The participant is in a condition to receive study drug and Tamoxifen (TAM) within 12 weeks after surgery or after adjuvant chemotherapy prior to study enrollment. Adjuvant chemotherapy prior to study is required to have been completed at the time of study enrollment.

9. The participant has ECOG performance status of grades 0 or 1 at the time of study enrollment.

10. The participant meets the following criteria of hepatic, renal and bone marrow functions on the laboratory test results at screening:

• Hepatic function: AST (GOT) = 3.0 times the upper limit of normal (ULN) ALT (GPT) = 3.0 times the ULN

• Renal function: serum creatinine level < 1.5 times the ULN

• Bone marrow function : white blood cell count = 3,000/mm3 platelet count = 100,000/µL hemoglobin = 10.0g/dL

11. The participant agrees to use a non-hormonal method of contraception through the study period.

Exclusion Criteria:

1. The participant has received neoadjuvant or adjuvant hormonal therapy for the latest breast cancer surgery.

2. The participant has received bilateral oophorectomy and bilateral ovarian irradiation.

3. The participant has inflammatory breast cancer or bilateral breast cancer.

4. The participant has non-invasive ductal carcinoma.

5. The participant has multiple primary cancers, or a history of carcinoma in other organs.

6. The participant is pregnant or breast-feeding.

7. The participant has a history of hypersensitivity to synthetic LH-RH, LH-RH derivative, TAM, TAM analogue (antiestrogen) or any component of the study drug.

8. The participant has a history of, or has been diagnosed with thromboembolism including myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism, or cardiac failure.

9. Patients whose QTcF interval exceeded 460 msec on the 12-lead electrocardiogram at screening.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Premenopausal Breast Cancer

Intervention

Drug:
• TAP-144-SR(6M)

• TAP-144-SR(3M)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48	Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.	Week 4 up to Week 48	No
Secondary	Concentration of Serum E2	The measure indicates serum E2 concentration at baseline and post-baseline time points.	Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673	No
Secondary	Concentration of Serum Luteinizing Hormone (LH)	This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).	Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673	No
Secondary	Concentration of Follicle Stimulating Hormone (FSH)	This measure indicates serum FSH concentration at baseline and post-baseline time points.	Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673	No
Secondary	Disease Free Survival (DFS) Rate at Week 96	DFS is defined as time from randomization to earliest day of onset the events, recurrence [including recurrence in the ipsilateral breast], secondary cancer [including breast cancer in the contralateral breast] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.	Week 96	No
Secondary	Distant Disease Free Survival (DDFS) Rate at Week 96	DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer [including breast cancer in the contralateral breast] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.	Week 96	No
Secondary	Serum Unchanged TAP-144 Level	This measure indicates the unchanged TAP-144 level in serum.	Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337	No
Secondary	QT Interval Measured by 12-lead Electrocardiogram (ECG)	12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).	Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337	Yes